Volume : 10, Issue : 02, February – 2023
Title:
12.APPLICATION OF BOX-BEHKEN DESIGN FOR PREPARATION OF LOMEFLOXACIN LOADED SOLID LIPID NANO PARTICLES FOR OCULAR DELIVERY
Authors :
Manthati Akanksha, Zeenath Ruhy
Abstract :
The aim of the present study was to optimize a solid lipid nanoparticle (SLN) of Lomifloxacin by investigating the relationship between design factors and experimental data using response surface methodology. A Box-Behnken design was constructed using solid lipid (X1), surfactant (X2), and drug/lipid ratio (X3) level as independent factors. SLN was successfully prepared by a modified method of melt-emulsion ultrasonication and low temperature- solidification technique using glyceryl monostearate as the solid lipid, and poloxamer 188 as the surfactant. The dependent variables were entrapment efficiency (EE), drug loading (DL), and turbidity. Properties of SLN such as the morphology, particle size, zeta potential, EE, DL, and drug release behavior were investigated, respectively. As a result, the nanoparticle designed showed nearly spherical particles with a mean particle size of 248 nm. The polydispersity index of particle size was 0.277 ± 0.058 and zeta potential was – 8.74 mV. The EE (%) and DL (%) could reach up to 83.29% ± 1.23% and 10.11% ± 2.02%, respectively. In vitro release studies showed a burst release at the initial stage followed by a prolonged release of Lomefloxacin from SLN up to 48 hours. The release kinetics of the optimized formulation best fitted the Peppas–Korsmeyer model. These results indicated that the Lomefloxacin-loaded SLN could potentially be exploited as a delivery system with improved drug entrapment efficiency and controlled drug release.
Keywords: Box-Behken Design, Lomefloxacin, Solid Lipid Nano Particles, Ocular Delivery
Cite This Article:
Please cite this article in press Manthati Akanksha et al, Application Of Box-Behken Design For Preparation Of Lomefloxacin Loaded Solid Lipid Nano Particles For Ocular Delivery., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. Abdollahi, S.; Lotfipour, F. PLGA-and PLA-based polymeric nanoparticles for antimicrobial drug delivery. Biomed. Int. 2015, 3, 1–11.
3. Das, S.; Suresh, P.K. Nanosuspension: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomed. Nanotechnol. Biol. Med. 2011, 7, 242–247. [CrossRef]
4. Gupta, H.; Aqil, M.; Khar, R.; Ali, A.; Bhatnagar, A.; Mittal, G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J. Drug Target. 2011, 19, 409–417. [CrossRef] [PubMed]
5. Bu, H.Z.; Gukasyan, H.J.; Goulet, L.; Lou, X.J.; Xiang, C.; Koudriakova, T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Met. 2007, 8, 91–107. [CrossRef] [PubMed]
6. Duxfield, L.; Sultana, R.; Wang, R.; Englebretsen, V.; Deo, S.; Rupenthal, I.D.; Al-Kassas, R. Ocular delivery systems for topical application of anti-infective agents. Drug Dev. Ind. Pharm. 2016, 42, 1–11. [CrossRef]
7. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
8. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
9. Takenouchi T, Ishii C, Sugawara M, Tokue Y, Ohya S: Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother. 1995 Jul;39(7):1414-8. [Article]
10. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993 Mar;37(3):483-90. [Article]